A non-XLA primary deficiency causes the earliest known defect of B cell differentiation in humans: a comparison with an XLA case.
We report a detailed comparison of B cell defects in two patients, one XLA and one non-XLA. Both had severe agammaglobulinemia with a total absence of CD19+ cells in the periphery. In the non-XLA case, CD19 expression was also highly impaired in the bone marrow, resulting in the absence of both B and preB compartments. Early proB cells were present since CD34+CD10+ and some CD19+CD10+ mostly CD34+ were identified, although diminished. By contrast, in the XLA patient the CD34+CD19+ proB cells were increased whereas the CD34-CD19+ preB cell population was low. Semi-quantitative RT-PCR analysis performed on mononuclear bone marrow cells from the non-XLA patient indicated that lambda-like, VpreB, Rag-1, Rag-2 and TdT transcripts expressed during proB cell stages were found at normal levels whereas E2A, CD10, Syk, Pax-5, CD19, Ig alpha, Ig beta, VH-C mu and V kappa-C kappa transcripts characteristic of later stages were severely depressed. By contrast in the XLA patient most of these transcripts were observed in normal amounts. The phenotype of the non-XLA patient resembles that of Pax-5 or Ig beta knock-out mice, but since the coding sequence of both cDNAs were shown to be normal, the blockage might rather result from an altered regulation of one of these genes or from defect of other genes. All these data indicate that the non-XLA patient suffers from a new genetic defect that results in an arrest of differentiation within the proB cell compartment, before the onset of Ig gene rearrangements. From all agammaglobulinemias reported so far, including XLA cases and those resulting from C mu gene defects, the non-XLA patient exhibits the earliest blockage in the B cell differentiation pathway.
Meffre
E
E
Centre d'Immunologie de Marseille-Luminy, France.
LeDeist
F
F
de Saint-Basile
G
G
Deville
A
A
Fougereau
M
M
Fischer
A
A
Schiff
C
C
D000361:Agammaglobulinemia / Q000276:immunology*; D015703:Antigens, CD / Q000032:analysis / Q000235:genetics; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology*; D001853:Bone Marrow; D051925:CD79 Antigens; D002454:Cell Differentiation; D002648:Child; D004268:DNA-Binding Proteins / Q000235:genetics; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009687:Nuclear Proteins / Q000235:genetics; D051757:PAX5 Transcription Factor; D010641:Phenotype; D011947:Receptors, Antigen, B-Cell / Q000235:genetics; D017422:Sequence Analysis, DNA; D014157:Transcription Factors; D014158:Transcription, Genetic
D015703:Antigens, CD; D051925:CD79 Antigens; C497881:CD79A protein, human; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D051757:PAX5 Transcription Factor; C497281:PAX5 protein, human; D011947:Receptors, Antigen, B-Cell; D014157:Transcription Factors